At MeaningCloud, we are proud to sponsor the Eye for Pharma Conference. Data, Evidence and Access Summit 2017. November 13-14th, 2017 – Philadelphia, US. MeaningCloud’s value proposition for the conference can be summarized as Text-Based Information with Artificial Intelligence.
Eye for Pharma is about demonstrating and communicating value, no matter which department you’re in. Whether it’s exploring innovative uses of real-world evidence (RWE) or creating new outcomes-based pricing models, only by embracing the power of data can you fully unlock the value of your drugs. It is a great opportunity for learning and networking.
Five reasons to attend:
- Crystal clarity. Gain 360-degree vision when navigating the complex US healthcare system – and slash time-to-market.
- The real-world revolution. Ensure RWE is making its mark throughout your development process, from proof of concept to pragmatic trials
- Know your value. Understand the true wishes of payers and other key stakeholders – and provide the evidence required to influence their decisions and boost your value proposition
- Industry-saving pricing models. How outcomes-based agreements can help guarantee reimbursement during times of rising costs and tightening budgets
- Stakeholders are the key. Why speculate when you can collaborate directly with key payers, FDA and other key influencers, all under one roof?
MeaningCloud’s value proposition: Text-Based Information with Artificial Intelligence by MeaningCloud
Text Analytics technologies automatically process and analyze textual content and provide valuable insights, transforming text-based “raw” data into structured, usable information.
MeaningCloud, as a Text Analytics provider, has evolved a highly specialized offering for the Health and Pharma industries, in particular in the areas of:
1. Patient experience
For pharmaceutical companies, it is vital to understand the feedback that their customers, both current and potential, express through all types of channels and contact points.
2. Adverse Drug Reactions, your products or the competitors’
Adverse Drug Reactions (ADR) are the biggest safety concern in the health field. Adverse Drug Reactions refer to harmful and unintended effects of drugs administered for the prevention and treatment of illness, both at normal dosages and in cases of incorrect usage or errors in medication. ADRs are the fourth cause of death for patients in hospitals in the U.S. Therefore, the pharmacovigilance area is receiving a great deal of attention at the moment, due to the high incidence of ADRs and the high associated costs (between 15 and 20 percent of hospital expenses are due to drug-related complications.)
3. HCP profiling
Health care professionals (HCPs) are very active on many social media platforms, including social networking platforms, blogs, and media-sharing sites.
HCPs are using social media improve health outcomes, develop a professional network, increase personal awareness of news and discoveries, motivate patients, and provide health information to the community.
Companies that can understand the profiles of HCPs can tap into valuable customer insights, new ways of marketing their products and services, and entirely new lines of business.
4. Automatization of Compliance investigation
No matter your specialty or the size of your practice or facility, there are healthcare compliance concerns that all medical organizations face. Healthcare organizations must be compliant with changing healthcare trends, guidelines, laws, and government regulations to minimize their risk.
Pharmaceutical companies are increasingly asked to provide information on how a product is dosed and applied in clinical practice, but also on compliance and adherence to therapy
To succeed in drug approval process, cost-effectiveness evidence is required, along with organizational, social and ethical evidence on the product.
Poor adherence to treatment is followed by a rise in morbidity rates, and therefore, a higher consumption of medical resources.
Medication non-adherence is one of the most crucial problems in the healthcare industry. For pharmaceutical companies, pharmacy benefit managers, and pharmacies, medication non-adherence significantly grinds down the profit due to non-adhering of medications by the patients. The growing interest of pharmaceutical companies and healthcare providers on medication adherence poses a greater influence on promoting better healthcare outcomes.
6. Drug shortages
National drug shortages, defined by the U.S. Food and Drug Administration (FDA) as a period when the demand or projected demand for a drug within the United States exceeds the supply of the drug, remain a complex and multilayered issue in the U.S. health care delivery system.
Drug shortages result in nearly $230 million in additional costs annually for hospitals because of the higher costs of substitute drugs.
Some suppliers are recognizing this opportunity and capitalizing on it.
7. Prescription medication sharing
It is illegal to share any prescription medication. Prescriptions are personal, meaning that if you possess the medication or drug, but the prescription is for a different person, then you are illegally possessing the drug. Taking prescription medication without a doctor’s approval is dangerous for anyone. The negative consequences of medicine sharing include unanticipated adverse events, complications of incorrect use, delay in seeking professional help, antibiotic resistance, and addiction or misuse related to the addictive properties of some medications.
8. Brands and products: The alarms and the opportunities
For pharmaceutical companies, it is vital to understand the feedback that their current and potential customers express through all types of channels and contact points about their brands, about their products, and their competitors.
Social media listening enables us to gather all that spontaneous benchmarking.
9. Information requests
To seek diagnosis or better care (see table), many patients are taking steps outside traditional doctor-patient relationships.
Health information exchange (HIE) offers tremendous potential for the future, but its widespread adoption and sustainability depend upon engaging patients and earning their trust.
Prevalence is a statistical concept referring to the number of cases of a disease that are present in a particular population at a given time, whereas incidence refers to the number of new cases that develop in a given period.
The prevalence of a condition may vary enormously from region to region.
We count among our clients some the largest companies in the Pharmaceutical industry. Join us in Philadelphia and visit our booth or attend our talk. If you are interested in attending the EyeforPharma Conference (November 13-14th, 2017 – Philadelphia, US), just drop us a line to firstname.lastname@example.org. We have an essential discount for you!
Stay tuned to access our presentation at the conference, that we will publish on this blog. In the meanwhile, if you are curious about how our technology works in the health area, just take a look at our Text Analytics Health Demo.
Looking forward to seeing you at the Eye for Pharma Conference!
Download this brochure
- Health and Pharma Companies Should Exploit Text-Based Information with Artificial Intelligence
- Benefits of Applying A.I. to Pharma and Life Sciences
Health and pharma companies can exploit their unstructured information
There are new kinds of data that are specific to the
healthcare and pharmaceutical industries (such as electronic health records) as well as data science tools that allow us to extract valuable knowledge from that data.
With MeaningCloud, it is possible to identify the costs of medical treatments, their efficiency (cost, benefits, and risks), references to drugs, side effects, or long-term results. That is why our text analytics solution for the healthcare and pharma domains has so much potential.